202 Carnegie Center, Suite 109 Princeton, New Jersey 08540 | VIA EDGAR |
May 12, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards
Re: | Oyster Point Pharma, Inc. |
Registration Statement on FormS-1 |
FileNo. 333-238194 |
Ladies and Gentlemen:
Oyster Point Pharma, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on FormS-1 (FileNo. 333-238194) (the“Registration Statement”) to become effective on Thursday, May 14, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Divakar Gupta and Ryan Sansom of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212)479-6474, or in his absence, Ryan Sansom of Cooley LLP at (617) 937-2335.
[Signature page follows]
Very truly yours,
Oyster Point Pharma, Inc. | ||
By: | /s/ Jeffrey Nau | |
Jeffrey Nau, Ph.D., M.M.S. | ||
President and Chief Executive Officer |
cc: | Daniel Lochner, Oyster Point Pharma, Inc. |
Divakar Gupta, Cooley LLP
Ryan Sansom, Cooley LLP
Brandon Fenn, Cooley LLP
Brian Cuneo, Latham & Watkins LLP
Nathan Ajiashvili, Latham & Watkins LLP